Loading
GPRC5D is a receptor on myeloma cells and in hair follicles, nails and taste buds. Talquetamab targets it without any test, and the side effects on skin, nails and taste follow from where it is expressed.
Talquetamab (Talvey) is a GPRC5D x CD3 bispecific labelled for relapsed or refractory multiple myeloma after at least four prior lines; the label names GPRC5D only as the target. Expression on plasma cells is high and independent of BCMA, which is why GPRC5D-directed therapy works after BCMA failure; GPRC5D loss at relapse has been described.
In plain words · GPRC5D is a second myeloma target used when BCMA-directed drugs stop working.
Talquetamab is given without a GPRC5D test. Because the same receptor sits in your skin, nails and taste buds, changes in taste, dry mouth, rash and nail problems are expected and are managed rather than treated as a sign the drug is not working.
Written only from the label or guideline text cited on this page. Not medical advice; your own report and the reading your team gives it come first.
The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.
“TALVEY is a bispecific GPRC5D-directed CD3 T-cell engager”
TALVEY prescribing information (DailyMed)No approval uses this readout as a threshold.
Matched on the name and aliases of the readout in the title, setting and summary of each trial; a match is a mention, not proof the readout was an entry criterion.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares the tags biomarker, surface-antigen, no-threshold.
Shares Antigen escape (antigen loss, lineage switch) and the tags biomarker, surface-antigen.